



## Agomab to Participate in Upcoming Investor Conferences

September 3, 2026

**Antwerp, Belgium, September 3, 2026** – [Agomab Therapeutics NV](#) (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences:

- **Citi's 2026 Biopharma Back to School Conference.** Thursday, September 10, 2026 in New York, NY.
- **2026 Cantor Global Healthcare Conference.** Fireside chat on Friday, September 11, 2026 at 8:00 AM ET in New York, NY.
- **H.C. Wainwright 28th Annual Global Investment Conference.** Fireside chat on Tuesday, September 15, 2026 at 2:00 PM ET in New York, NY.
- **Morgan Stanley 24th Annual Global Healthcare Conference.** Fireside chat on Wednesday, September 16, 2026 at 9:15 AM ET in New York, NY.

### About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab's product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab's mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

### Contacts

#### Investors

Sofie Van Gijssel

VP of Investor Relations

E-Mail: [sofie.vangijssel@agomab.com](mailto:sofie.vangijssel@agomab.com)

Phone: +1 781 296 1143

#### Media

Gretchen Schweitzer

Trophic Communications

E-Mail: [agomab@trophic.eu](mailto:agomab@trophic.eu)

Phone: +49 172 861 8540